Project Grant R41HL177866
Award Date
6/1/25
Completion Date
5/31/26
Dollars Obligated
$307K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Wisconsin, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $1,249,317 project grant to Sanaheal Inc. to optimize and validate a hemostatic bioadhesive paste for coagulation-independent rapid control of bleeding. The objective is to develop this innovative solution to effectively treat high-risk bleeding in anticoagulated or coagulopathic patients, which addresses the limitations of existing hemostatic agents....
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,000,000 in funding to Novomedix LLC, a woman-owned small business in San Diego, California. The funding supports the development and validation of methods for analyzing the active pharmaceutical ingredient, as well as GLP toxicity and toxicology studies in rats and dogs, for a novel small molecule therapy that aims to protect against...
This $1,488,899 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the advanced development and validation of two innovative compounds, YT-002 and YT-004, targeting protein kinase C to preserve myocardial tissue and function following heart attacks. The research aims to optimize the pharmacokinetic and pharmacodynamic profiles of these compounds, conduct long-term safety and efficacy studies...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,182,632 to Eydis Bio, Inc. to further develop their lead compound HS-276 as a potential treatment for systemic sclerosis-associated interstitial lung disease (SSc-ILD). The key activities funded under this 2-year award include: 1) conducting in vivo pharmacodynamic studies of HS-276 in murine lung fibrosis models, 2) evaluating...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $127,305 to The Children's Hospital Corporation (dba Boston Children's Hospital) for a research project titled "Unraveling Immune Cell Interactions and Multicellular Dynamics in GNAQ-Driven Capillary Malformation." The project aims to study the mechanisms behind capillary malformations, which are vascular...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $308,526 to Lucie Medical Inc. to develop a novel device for uterine hemostasis (bleeding control) after Cesarean sections. The project aims to finalize the design, validate materials, and test the functional performance of this new system, which is intended to help address the significant challenge of postpartum hemorrhage - a leading...
This $347,608 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a novel, oral, once-daily immunoregulatory therapeutic for the treatment of asthma by Biotherapeutics, Inc., an emerging biotechnology company. The goal is to characterize the therapeutic efficacy and administration route of the drug candidate in mouse models of asthma, and determine its translational potential...
This Project Grant award of $999,998.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports the development of a novel long-acting conjugate of the vasodilative hormone, human brain natriuretic peptide (HBNP), to treat resistant hypertension. The awardee, Antlia Bioscience, Inc., will pursue the bulk manufacture of clinical-grade PAS(400)-HBNP, conduct dose-range-finding pharmacokinetic and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $355,935 to Biotherapeutics, Inc., a biotechnology company located in Blacksburg, Virginia. The grant funding supports the development of a novel, oral immunoregulatory therapeutic for treating asthma. The key objectives are to characterize the therapeutic efficacy and optimal route of administration in mouse models of asthma, and...
This federal Project Grant award of $1,158,000 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to develop chemical modulators for the BCL11A protein, a validated target for treating sickle cell disease and beta-thalassemia. The goal is to leverage proximity-based protein depletion techniques, such as proteolysis targeting chimeras (PROTACs) and molecular glues, to effectively reduce BCL11A levels...